tetano
Editor, Senior Moderator
Inflammopharmacology
. 2022 Aug 10.
doi: 10.1007/s10787-022-01040-9. Online ahead of print.
Pathogenic role of cytokines in COVID-19, its association with contributing co-morbidities and possible therapeutic regimens
Ayesha Tanveer[SUP] 1 [/SUP], Bushra Akhtar[SUP] 2 [/SUP], Ali Sharif[SUP] 3 [/SUP], Uzma Saleem[SUP] 4 [/SUP], Azhar Rasul[SUP] 5 [/SUP], Aftab Ahmad[SUP] 6 7 [/SUP], Kashif Jilani[SUP] 6 [/SUP]
Affiliations
Abstract
The Covid-19, a threatening pandemic, was originated from China in December 2019 and spread quickly to all over the world. The pathogenesis of coronavirus is linked with the disproportionate response of the immune system. This involves the systemic inflammatory reaction which is characterized by marked pro-inflammatory cytokine release commonly known as cytokine release storm (CRS). The pro inflammatory cytokines are involved in cascade of pulmonary inflammation, hyper coagulation and thrombosis which may be lethal for the individual. That's why, it is very important to have understanding of pro inflammatory cytokines and their pathological role in SARS-CoV-2. The pathogenesis of Covid is not the same in every individual, it can vary due to the presence of pre-existing comorbidities like suffering from already an inflammatory disease such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), an immune-compromised patients suffering from Diabetes Mellitus (DM) and Tuberculosis (TB) are more vulnerable morbidity and complications following COVID-19. This review is particularly related to COVID-19 patients having comorbidity of other inflammatory diseases. We have discussed the brief pathogenesis of COVID-19 and cytokines release storm with reference to other co-morbidities including RA, IBD, COPD, DM and TB. The available therapeutic regimens for COVID-19 including cytokine inhibitors, anti-viral, anti-biotic, bronchodilators, JAK- inhibitors, immunomodulators and anti-fibrotic agents have also been discussed briefly. Moreover, newly emerging medicines in the clinical trials have also been discussed which are found to be effective in treating Covid-19.
Keywords: COVID-19; Cytokines release storm; Inflammatory diseases; Therapeutic interventions.
. 2022 Aug 10.
doi: 10.1007/s10787-022-01040-9. Online ahead of print.
Pathogenic role of cytokines in COVID-19, its association with contributing co-morbidities and possible therapeutic regimens
Ayesha Tanveer[SUP] 1 [/SUP], Bushra Akhtar[SUP] 2 [/SUP], Ali Sharif[SUP] 3 [/SUP], Uzma Saleem[SUP] 4 [/SUP], Azhar Rasul[SUP] 5 [/SUP], Aftab Ahmad[SUP] 6 7 [/SUP], Kashif Jilani[SUP] 6 [/SUP]
Affiliations
- PMID: 35948809
- DOI: 10.1007/s10787-022-01040-9
Abstract
The Covid-19, a threatening pandemic, was originated from China in December 2019 and spread quickly to all over the world. The pathogenesis of coronavirus is linked with the disproportionate response of the immune system. This involves the systemic inflammatory reaction which is characterized by marked pro-inflammatory cytokine release commonly known as cytokine release storm (CRS). The pro inflammatory cytokines are involved in cascade of pulmonary inflammation, hyper coagulation and thrombosis which may be lethal for the individual. That's why, it is very important to have understanding of pro inflammatory cytokines and their pathological role in SARS-CoV-2. The pathogenesis of Covid is not the same in every individual, it can vary due to the presence of pre-existing comorbidities like suffering from already an inflammatory disease such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), an immune-compromised patients suffering from Diabetes Mellitus (DM) and Tuberculosis (TB) are more vulnerable morbidity and complications following COVID-19. This review is particularly related to COVID-19 patients having comorbidity of other inflammatory diseases. We have discussed the brief pathogenesis of COVID-19 and cytokines release storm with reference to other co-morbidities including RA, IBD, COPD, DM and TB. The available therapeutic regimens for COVID-19 including cytokine inhibitors, anti-viral, anti-biotic, bronchodilators, JAK- inhibitors, immunomodulators and anti-fibrotic agents have also been discussed briefly. Moreover, newly emerging medicines in the clinical trials have also been discussed which are found to be effective in treating Covid-19.
Keywords: COVID-19; Cytokines release storm; Inflammatory diseases; Therapeutic interventions.